ID   SK-MEL-21
AC   CVCL_3877
SY   SK-Mel-21; SK MEL 21; SK-MEL21; AN-Mel
DR   BTO; BTO:0002966
DR   cancercelllines; CVCL_3877
DR   Cosmic; 897471
DR   Cosmic; 923386
DR   Cosmic; 933127
DR   Cosmic; 1669137
DR   Wikidata; Q54953923
RX   DOI=10.1007/978-1-4615-7228-2_39;
RX   Patent=US4591572;
RX   PubMed=327080;
RX   PubMed=1067619;
RX   PubMed=3518877;
RX   PubMed=6197381;
RX   PubMed=6864164;
RX   PubMed=6933476;
RX   PubMed=7747814;
RX   PubMed=9598804;
RX   PubMed=21725359;
RX   PubMed=24576830;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Characteristics: Very highly pigmented.
CC   Sequence variation: Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Heterozygous (PubMed=9598804).
CC   Sequence variation: Mutation; HGNC; 1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Unspecified (PubMed=9598804).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830).
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   35Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 21
//
RX   DOI=10.1007/978-1-4615-7228-2_39;
RA   Houghton A.N., Oettgen H.F., Old L.J.;
RT   "Malignant melanoma. Current status of the search for melanoma-specific
RT   antigens.";
RL   (In) Immunodermatology. Comprehensive Immunology, Vol 7; Safai B., Good R.A. (eds.); pp.557-576; Springer; Boston (1981).
//
RX   Patent=US4591572;
RA   Mattes M.J., Thomson T.M., Old L.J., Lloyd K.O.;
RT   "Pigmentation associated, differentiation antigen of human melanoma
RT   and autologous antibody.";
RL   Patent number US4591572, 27-May-1986.
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=1067619; DOI=10.1073/pnas.73.9.3278;
RA   Carey T.E., Takahashi T., Resnick-Silverman L.A., Oettgen H.F.,
RA   Old L.J.;
RT   "Cell surface antigens of human malignant melanoma: mixed
RT   hemadsorption assays for humoral immunity to cultured autologous
RT   melanoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 73:3278-3282(1976).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6197381; DOI=10.1002/ijc.2910320610;
RA   Mattes M.J., Thomson T.M., Old L.J., Lloyd K.O.;
RT   "A pigmentation-associated, differentiation antigen of human melanoma
RT   defined by a precipitating antibody in human serum.";
RL   Int. J. Cancer 32:717-721(1983).
//
RX   PubMed=6864164; DOI=10.1084/jem.158.1.53;
RA   Houghton A.N., Brooks H., Cote R.J., Taormina M.C., Oettgen H.F.,
RA   Old L.J.;
RT   "Detection of cell surface and intracellular antigens by human
RT   monoclonal antibodies. Hybrid cell lines derived from lymphocytes of
RT   patients with malignant melanoma.";
RL   J. Exp. Med. 158:53-65(1983).
//
RX   PubMed=6933476; DOI=10.1073/pnas.77.7.4260;
RA   Houghton A.N., Taormina M.C., Ikeda H., Watanabe T., Oettgen H.F.,
RA   Old L.J.;
RT   "Serological survey of normal humans for natural antibody to cell
RT   surface antigens of melanoma.";
RL   Proc. Natl. Acad. Sci. U.S.A. 77:4260-4264(1980).
//
RX   PubMed=7747814;
RA   Gruis N.A., Weaver-Feldhaus J.M., Liu Q.-Y., Frye C., Eeles R., Orlow I.,
RA   Lacombe L., Ponce-Castaneda V., Lianes P., Latres E., Skolnick M.H.,
RA   Cordon-Cardo C., Kamb A.;
RT   "Genetic evidence in melanoma and bladder cancers that p16 and p53
RT   function in separate pathways of tumor suppression.";
RL   Am. J. Pathol. 146:1199-1206(1995).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker G.J., Flores J.F., Glendening J.M., Lin A.H.-T., Markl I.D.C.,
RA   Fountain J.W.;
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//
RX   PubMed=21725359; DOI=10.1038/onc.2011.250;
RA   Xing F., Persaud Y., Pratilas C.A., Taylor B.S., Janakiraman M.,
RA   She Q.-B., Gallardo H., Liu C., Merghoub T., Hefter B., Dolgalev I.,
RA   Viale A.J., Heguy A., de Stanchina E., Cobrinik D., Bollag G.,
RA   Wolchok J.D., Houghton A.N., Solit D.B.;
RT   "Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF
RT   dependence in melanomas harboring (V600E)BRAF.";
RL   Oncogene 31:446-457(2012).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625;
RA   Nissan M.H., Pratilas C.A., Jones A.M., Ramirez R., Won H., Liu C.-L.,
RA   Tiwari S., Kong L., Hanrahan A.J., Yao Z., Merghoub T., Ribas A.,
RA   Chapman P.B., Yaeger R., Taylor B.S., Schultz N., Berger M.F.,
RA   Rosen N., Solit D.B.;
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//